NCT04257045

Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 46 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This trial collects information about factors that affect communication of genetic test results, decision-making, and access to genetic testing in women with hereditary gynecological cancers. Studying individuals who are positive for a genetic mutation and immediate biological family members (including a parent, full-sibling, or child) may help identify cancer genes and other persons at risk.

Detailed description

PRIMARY OBJECTIVES: I. Identify and explore factors influencing the communication of genetic testing results from probands (patients with confirmed hereditary cancer predisposition syndrome) to their first-degree relatives. (Step 1) II. Identify and explore factors influencing decision making and pursuit of cascade testing among first-degree relatives of probands. (Step 1) III. Estimate the uptake of cascade testing by first-degree relatives of probands at a safety-net hospital and the uptake of cascade testing by first-degree relatives of probands at a comprehensive cancer center. (Step 2) IV. Estimate the frequency of reported factors that influence communication, decision-making, and pursuit of cascade testing among probands and their first-degree family members at a safety-net hospital and at a comprehensive cancer center. (Step 2) V. Explore similarities and differences in cascade genetic testing rates and reported barriers to cascade genetic testing of first-degree relatives at probands from a safety-net hospital and a comprehensive cancer center. (Step 2) OUTLINE: STEP I: Patients and first degree relatives participate in semi-structure, in-depth interviews about genetic testing over 45-60 minutes. STEP II: Patients and first degree relatives complete survey questionnaires over 20 minutes.

Conditions

• Breast Carcinoma
• Deleterious CDH1 Gene Mutation
• Deleterious DICER1 Gene Mutation
• Deleterious SMARCA4 Gene Mutation
• Deleterious STK11 Gene Mutation
• Endometrial Carcinoma
• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Primary Peritoneal Carcinoma

Interventions

Type	Name	Description
OTHER	Interview	Participate in semi-structure, in-depth qualitative interviews
OTHER	Questionnaire Administration	Complete questionnaires
OTHER	Survey Administration	Complete survey

Timeline

• Start date: 2019-08-21
• Primary completion: 2024-07-09
• Completion: 2024-07-09
• First posted: 2020-02-05
• Last updated: 2024-07-12

Locations

2 sites across 1 country: United States